JP2015500833A5 - - Google Patents

Download PDF

Info

Publication number
JP2015500833A5
JP2015500833A5 JP2014545985A JP2014545985A JP2015500833A5 JP 2015500833 A5 JP2015500833 A5 JP 2015500833A5 JP 2014545985 A JP2014545985 A JP 2014545985A JP 2014545985 A JP2014545985 A JP 2014545985A JP 2015500833 A5 JP2015500833 A5 JP 2015500833A5
Authority
JP
Japan
Prior art keywords
salt
compound
composition
hydrogen
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014545985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500833A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/067799 external-priority patent/WO2013085922A1/en
Publication of JP2015500833A publication Critical patent/JP2015500833A/ja
Publication of JP2015500833A5 publication Critical patent/JP2015500833A5/ja
Pending legal-status Critical Current

Links

JP2014545985A 2011-12-09 2012-12-04 ノルイボガインのリン酸エステル Pending JP2015500833A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161569150P 2011-12-09 2011-12-09
US61/569,150 2011-12-09
PCT/US2012/067799 WO2013085922A1 (en) 2011-12-09 2012-12-04 Phosphate esters of noribogaine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017161035A Division JP2017203047A (ja) 2011-12-09 2017-08-24 ノルイボガインのリン酸エステル

Publications (2)

Publication Number Publication Date
JP2015500833A JP2015500833A (ja) 2015-01-08
JP2015500833A5 true JP2015500833A5 (enExample) 2016-01-28

Family

ID=48574807

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014545985A Pending JP2015500833A (ja) 2011-12-09 2012-12-04 ノルイボガインのリン酸エステル
JP2017161035A Pending JP2017203047A (ja) 2011-12-09 2017-08-24 ノルイボガインのリン酸エステル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017161035A Pending JP2017203047A (ja) 2011-12-09 2017-08-24 ノルイボガインのリン酸エステル

Country Status (5)

Country Link
US (2) US9051343B2 (enExample)
EP (1) EP2788003A4 (enExample)
JP (2) JP2015500833A (enExample)
CA (1) CA2855994A1 (enExample)
WO (1) WO2013085922A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2855994A1 (en) * 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
WO2014098877A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) * 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
WO2014143201A1 (en) * 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
EP3164402A1 (en) * 2014-04-21 2017-05-10 DemeRx, Inc. N-substituted noribogaine prodrugs
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
AU2015353414B2 (en) 2014-11-26 2021-04-29 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN112105734A (zh) 2018-03-08 2020-12-18 新图集生物技术有限责任公司 生产色胺的方法
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
EP3747992A1 (en) 2019-06-04 2020-12-09 Medizinische Hochschule Hannover Compositions and process for integrating cells into epithelium
WO2024145462A1 (en) * 2022-12-29 2024-07-04 Atai Therapeutics, Inc. Ibogaine and noribogaine analogs and methods of use

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2813873A (en) 1957-11-19 Derivatives of the ibogaine alkaloids
GB841697A (en) 1956-03-22 1960-07-20 Ciba Ltd Analgesic compositions
GB924042A (en) 1959-03-05 1963-04-18 Geigy Ag J R Process for the decarboxylation of alkyl esters of unsaturated, nitrogen-containing carboxylic acids
US3639408A (en) 1967-06-03 1972-02-01 Shionogi & Co Process for the preparation of isoquinuclidine derivatives
US3516989A (en) 1967-10-02 1970-06-23 American Home Prod Intermediates for total synthesis of iboga alkaloids and means of preparation
FR7131M (enExample) 1968-01-31 1969-07-21
US3557126A (en) 1969-08-14 1971-01-19 American Home Prod Derivatives of iboga alkaloids
US3574220A (en) 1969-08-14 1971-04-06 American Home Prod 1,7-methano-1h-1-benzazepin-5(4h)-ones
CA982478A (en) 1971-04-12 1976-01-27 Jerome Berk Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4375414A (en) 1971-05-20 1983-03-01 Meir Strahilevitz Immunological methods for removing species from the blood circulatory system and devices therefor
US3715361A (en) 1971-10-08 1973-02-06 American Cyanamid Co Acyl derivatives of 10-methoxyibogamine
US3875011A (en) 1972-11-06 1975-04-01 Syva Co Enzyme immunoassays with glucose-6-phosphate dehydrogenase
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
FR2296418B1 (enExample) 1974-12-30 1978-07-21 Anvar
US4272541A (en) 1978-06-02 1981-06-09 Miles Laboratories, Inc. 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
CA1188989A (en) 1981-05-21 1985-06-18 Richard R. Scherschlicht Nonapeptide for the treatment of drug withdrawal symptoms
US4604365A (en) 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4499096A (en) 1983-11-18 1985-02-12 Lotsof Howard S Rapid method for interrupting the narcotic addiction syndrome
US5266574A (en) 1984-04-09 1993-11-30 Ian S. Zagon Growth regulation and related applications of opioid antagonists
US4626539A (en) 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
ATE95430T1 (de) 1984-12-22 1993-10-15 Sanol Arznei Schwarz Gmbh Wirkstoffpflaster.
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4587243A (en) 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
US4857523A (en) 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome
US5629307A (en) 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
DE4010079A1 (de) 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5026697A (en) 1990-05-30 1991-06-25 Nda International, Inc. Rapid method for interrupting or attenuating the nicotine/tobacco dependency syndrome
US5152994A (en) 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5283247A (en) 1991-02-06 1994-02-01 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5149538A (en) 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5290784A (en) 1991-07-18 1994-03-01 Yueqian Qu Aconitane derivatives used as a medication to treat addiction
ATE170077T1 (de) 1992-04-10 1998-09-15 Merrell Pharma Inc Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
CZ281630B6 (cs) 1992-06-12 1996-11-13 Des-Tyr Dynorphin Partnership Analogy des-tyr dynorfinu
US5256669A (en) 1992-08-07 1993-10-26 Aminotek Sciences, Inc. Methods and compositions for treating acute or chronic pain and drug addiction
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
CA2145207A1 (en) 1992-09-21 1994-03-22 Bo-Yi Qin Methods for identifying and using low/non-addictive opioid analgesics
CN1042895C (zh) 1992-09-23 1999-04-14 曲曰谦 治疗吸毒者戒断综合症及脱瘾的药物组合物
AU4066693A (en) 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
US5865444A (en) 1994-03-21 1999-02-02 Deere & Company Body leveling suspension including a pivoting arrangement
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5552406A (en) 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
ES2264562T3 (es) * 1994-07-25 2007-01-01 Nda International, Inc. Uso de derivados de noribogaina para tratar la dependencia quimica en mamiferos.
US5591738A (en) 1994-10-14 1997-01-07 Nda International, Inc. Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof
DE69635737D1 (de) 1995-08-08 2006-04-06 Albany Medical College Albany Ibogamin verwandte verbindungen
US5760044A (en) 1996-05-16 1998-06-02 Archer; Sydney Method for treating cocaine and amphetamine dependency
WO1997044317A2 (en) 1996-05-21 1997-11-27 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Novel methods of o-demethylation and n-deprotection
GB9702701D0 (en) * 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
ES2395268T3 (es) 1997-09-04 2013-02-11 Demerx, Inc. Noribogaína para el tratamiento del dolor y la drogadicción
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
EA008476B1 (ru) 2001-06-11 2007-06-29 Биовитрум Аб Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii
US20030153552A1 (en) 2002-02-14 2003-08-14 Mash Deborah C. Method of treating chemical dependency in mammals and a composition therefor
US6864271B2 (en) 2002-11-12 2005-03-08 The Foundation For The Lsu Health Sciences Center Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
US6806291B1 (en) 2003-10-09 2004-10-19 The Foundation For The Lsu Health Sciences Center Analgesic compounds, their synthesis and pharmaceutical compositions containing them
JP2007511542A (ja) * 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
EP1757585B1 (en) 2005-08-26 2010-12-01 Medical Research Council Anionically substituted 7-Nitroindoline derivatives and their uses
CA2630314A1 (en) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 1,5-substituted indol-2-yl amide derivatives
EP1998766A2 (en) * 2005-12-16 2008-12-10 Ironwood Pharmaceuticals, Inc. Useful indole compounds
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
PA8843701A1 (es) * 2008-09-29 2010-05-26 Abbott Lab Derivados de indolina y métodos para usarlos
JP6141016B2 (ja) * 2009-08-27 2017-06-07 バイオノミックス リミテッド 増殖性疾患の治療のための併用療法
US8362007B1 (en) * 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) * 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
BR112014005064A2 (pt) 2011-09-15 2017-04-04 Demerx Inc não solvatos de sal de norigobaína
CA2855994A1 (en) * 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
WO2014098877A1 (en) * 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) * 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US20150258104A1 (en) * 2014-03-13 2015-09-17 Demerx, Inc. Use of noribogaine for the treatment of pain

Similar Documents

Publication Publication Date Title
JP2015500833A5 (enExample)
JP2013532652A5 (enExample)
JP2015509075A5 (enExample)
NZ631477A (en) Substituted pyrrolidine-2-carboxamides
EA201201031A1 (ru) Ингибиторы вируса гепатита с
SI3212174T1 (en) Procedures for the treatment of infections with filoviridae virus
JP2011037841A5 (enExample)
RU2011127079A (ru) Комбинация производного циклоспорина и нуклеозидов для лечения инфекции вирусом гепатита с
WO2011027249A3 (en) Benzimidazole derivatives
JP2012532136A5 (enExample)
BR112013029692A2 (pt) derivados de imidazol úteis para o tratamento da artrite
EP2581376A4 (en) MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF
WO2009082818A8 (en) Novel c-21-keto lupane derivatives preparation and use thereof
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
CY1117576T1 (el) Δινουκλεοτιδικα προφαρμακα
CY1122809T1 (el) Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων
BR112015028501B8 (pt) Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico
MY148636A (en) Benzimidazole derivatives
EA201190099A1 (ru) (1-фенил-2-пиридин-4-ил)этиловые эфиры бензойной кислоты в качестве ингибиторов фосфодиэстеразы
NZ627274A (en) Anesthetic compounds and related methods of use
WO2014078295A8 (en) Gemcitabine prodrugs and uses thereof
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
WO2012018534A3 (en) Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
JP2012526148A5 (enExample)
JP2015500885A5 (enExample)